References
1. Reeve E. [Placeholder for Reeve article to be published in same
issue]. 2023.
2. Bloomfield HE, Greer N, Linsky AM, et al. Deprescribing for
Community-Dwelling Older Adults: a Systematic Review and Meta-analysis.J Gen Intern Med. 2020;35(11):3323-3332.
3. Kua CH, Mak VSL, Huey Lee SW. Health Outcomes of Deprescribing
Interventions Among Older Residents in Nursing Homes: A Systematic
Review and Meta-analysis. J Am Med Dir Assoc. 2019;20(3):362-372
e311.
4. Thompson W, Reeve E, Moriarty F, et al. Deprescribing: Future
directions for research. Res Social Adm Pharm.2019;15(6):801-805.
5. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of
inappropriate benzodiazepine prescriptions among older adults through
direct patient education: the EMPOWER cluster randomized trial.JAMA Intern Med. 2014;174(6):890-898.
6. Steinman MA, Boyd CM, Spar MJ, Norton JD, Tannenbaum C. Deprescribing
and deimplementation: Time for transformative change. J Am Geriatr
Soc. 2021.
7. McConeghy KW, Cinque M, White EM, et al. Lessons for deprescribing
from a nonessential medication hold policy in US nursing homes. J
Am Geriatr Soc. 2022;70(2):429-438.
8. Ross JS, Frazee SG, Garavaglia SB, et al. Trends in use of ezetimibe
after the ENHANCE trial, 2007 through 2010. JAMA Intern Med.2014;174(9):1486-1493.
9. Sheppard JP, Burt J, Lown M, et al. Effect of Antihypertensive
Medication Reduction vs Usual Care on Short-term Blood Pressure Control
in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE
Randomized Clinical Trial. JAMA. 2020;323(20):2039-2051.
10. Brownell KD, Roberto CA. Strategic science with policy impact.Lancet. 2015;385(9986):2445-2446.